54 results about "Lactate dehydrogenases" patented technology

The present disclosure provides novel small molecule compounds with six-membered aromatic substituents that can serve as inhibitors of lactate dehydrogenase. The present disclosure also provides pharmaceutical compositions, comprising at least one of such novel substituted compounds, and methods of using at least one of such compounds or compositions in treating or preventing diseases associated with lactate dehydrogenase activities, such as autoimmune diseases.

The present disclosure provides novel substituted pyrrole compounds that can serve as inhibitors of lactate dehydrogenase, pharmaceutical compositions, comprising at least one of such novel substituted pyrrole compounds, and methods of using at least one of such compounds or compositions in treating or preventing diseases associated with lactate dehydrogenase activities, such as primary hyperoxaluria.

The present disclosure relates to a genetically modified microorganism satisfying some of predetermined conditions. The predetermined conditions include: (I) succinate dehydrogenase activity or fumarate reductase activity being reduced or inactivated relative to a wild-type microorganism; (II) lactate dehydrogenase activity being reduced or inactivated relative to the wild-type microorganism; (III) the genetically modified microorganism having modified phosphoenolpyruvate carboxylase activity showing resistance to feedback inhibition by aspartic acid in wild-type phosphoenolpyruvate carboxylase activity, or exogenous phosphoenolpyruvate carboxylase activity having higher resistance to feedback inhibition by aspartic acid than that of the wild-type phosphoenolpyruvate carboxylase activity shown by the wild-type microorganism; and (IV) pyruvate:quinone oxidoreductase being reduced or inactivated relative to the wild-type microorganism.

The application relates to the frontiers of nanomaterials and drug screening fields, and discloses a fluorescent probe material for drug screening and a drug screening method. The fluorescent probe material realizes screening of anticancer drug efficacy of a to-be-detected drug by detecting the concentration of an NAD+ (nicotinamide adenine dinucleotide) active marker of lactate dehydrogenase, the fluorescent probe material comprises an A agent and a B agent, the A agent is a covalent organic framework material loaded with carbon dots with reducibility, and is denoted as COF@CDs, and the B agent is a transition metal hydride; the transition metal hydride can make NAD+ hydrogenated and reduced into NADH in the presence of the COF@CDs; the product after hydrogen loss of the transition metal hydride can be combined with the COF@CDs, and the COF@CDs can emit fluorescence under excitation light, and the fluorescence is quenched.

The present disclosure provides novel substituted pyrrole compounds that can serve as inhibitors of lactate dehydrogenase, pharmaceutical compositions, comprising at least one of such novel substituted pyrrole compounds, and methods of using at least one of such compounds or compositions in treating or preventing diseases associated with lactate dehydrogenase activities, such as primary hyperoxaluria.

The invention discloses engineering probiotics for expressing D-lactic dehydrogenase as well as a construction method and application of the engineering probiotics, and belongs to the technical field of biological medicines. The engineering probiotics disclosed by the invention are constructed by taking escherichia coli Nissle 1917 as an original strain and exogenously transferring a coding gene of D-lactic dehydrogenase into the original strain. By means of synthetic biology, a living body treatment factory capable of removing specific metabolites in situ is constructed, and treatment normal form transformation from protein inhibition to metabolite removal is achieved; through a lipid coating technology, oral delivery and intestinal targeted colonization of engineering bacteria are realized, and the treatment accuracy and efficiency are improved; transformation is carried out based on probiotics EcN, so that the biological safety is high; the treatment process is oral administration and is non-invasive, and systemic toxic and side effects of traditional chemotherapy are avoided.

The invention discloses an application of compounds N-(1-naphthyl)-2-phenoxy acetamide and N-(1-naphthyl)-2-(phenylamino) ethyl thioamide in preparation of cryptosporidium resisting medicines, and belongs to the technical field of medicines and veterinary medicines of anti-parasitic medicines. The compound is obtained through functional group modification by taking NSC158011 as a pilot structure and can efficiently inhibit the activity of cryptosporidium parvum lactic dehydrogenase, and the inhibition rates respectively reach 60-70% and gt; 90%. An in-vitro experiment shows that parasite load is obviously reduced in HCT-8 cells by the two; in vivo, in a gamma-interferon gene knockout mouse and calf infection model, the fecal oocyst load is reduced by 40-100 times, the intestinal barrier repair can be promoted, and the safety is good. The invention reveals that the compound has efficient insect-resistant activity, high safety and intestinal protection effect for the first time, and provides important material basis and technical support for developing a new generation of cryptosporidium-resistant drugs.

[Problem] To provide a measurement reagent which contains lactate dehydrogenase, wherein the stability of the lactate dehydrogenase is improved in order to enable the measurement reagent to be used for a long period of time; and to provide a method for improving the stability of the lactate dehydrogenase. [Solution] An alkali metal compound is included in a reagent containing lactate dehydrogenase.

The invention relates to the use of an antitumor vaccine composed of two nine-amino-acid peptides - the original, cryptic TERT572 (RLFFYRKSV, SEQ ID NO:1) expressed by tumor cells and its optimized variant TERT572Y (YLFFYRKSV, SEQ ID NO: 2), for the treatment of a tumor expressing telomerase reverse transcriptase (TERT) in an HLA-A*0201 patient with normal levels of gamma-glutamyl transferase (gGT) and / or lactate dehydrogenase (LDH).

The present invention discloses the use of a traditional Chinese medicine composition in the preparation of a drug for preventing or treating diabetic cardiomyopathy. The traditional Chinese medicine composition of the present invention is composed of notopterygium root, angelica dahurica, Poria cocos, saposhnikovia root, schizonepeta tenuifolia, ligusticum wallichii, chuanxiong rhizome, platycodon grandiflorum, bupleurum root, peucedanum chinense, fructus aurantii, and liquorice. Pharmacodynamic experimental results show that the traditional Chinese medicine composition of the present invention can reduce serum creatine kinase isoenzyme (CK-MB) and lactate dehydrogenase (LDH) levels, and can significantly improve diabetic myocardial cell damage; reduce cardiac index, improve myocardial hypertrophy and left ventricular remodeling, and has the effect of preventing and treating diabetic cardiomyopathy.

This invention discloses a lactate reactor capable of inhibiting intervertebral disc degeneration and its preparation method. The lactate reactor is an injectable gel microsphere loaded with lactate-catalyzing nanoparticles and matrix cell-derived factor SDF-1α. The lactate-catalyzing nanoparticles are mesoporous silica nanoparticles, whose mesopores are coated with lactate dehydrogenase, nicotinamide adenine dinucleotide, alanine aminotransferase, and glutamate, and whose surface is coated with an oxidized sodium alginate layer via a Schiff base reaction. This invention can efficiently convert pathological lactate in the nucleus pulposus microenvironment into alanine, which inhibits degeneration, while simultaneously recruiting stem cells to synergistically inhibit the process of intervertebral disc degeneration.

The invention provides a method for evaluating acute gastrointestinal toxicity of a test substance based on a Caco-2 cell model, which is characterized by comprising the following steps: acquiring Caco-2 monolayer cells; enabling the Caco-2 monolayer cells to be in contact with a test substance; detecting the amount of fluorescein penetrating through the Caco-2 monolayer cells before and after contact; and / or detecting the amount of Evans blue penetrating through the Caco-2 monolayer cells before and after contact; and / or detecting the activity change of lactic dehydrogenase in the Caco-2 monolayer cell external culture medium before and after contact; and evaluating the acute gastrointestinal toxicity of the test substance according to the detection result.

The present disclosure provides novel substituted pyrrole compounds useful as lactate dehydrogenase A inhibitors, pharmaceutical compositions comprising at least one such novel substituted pyrrole compound, and methods of treating or preventing diseases associated with lactate dehydrogenase A activity, such as cancer, using at least one such compound or composition.

The present invention relates to compositions and methods of use thereof. Methods are drawn towards treating oxalate production-related disease or disorder by inhibiting the activity of glycolate oxidase (GO) and lactate dehydrogenase (LDHA) while activating degradation of GO and / or LDHA.

The present application belongs to the technical field of bioengineering, and particularly relates to a tuna fish bone antioxidant oligopeptide and a preparation method thereof.The tuna fish bone antioxidant oligopeptide has good scavenging activity, and has good thermal stability and digestion resistance; the mechanism of action is to promote the release of nitric oxide (NO), improve the levels of superoxide dismutase (SOD), glutathione peroxidase (GSH-PX), catalase (CAT) and total antioxidant capacity (T-AOC), and reduce the levels of malondialdehyde (MDA) and lactate dehydrogenase (LDH); JQYG-1 can protect HUVEC cells from oxidative damage induced by hydrogen peroxide; JQYG-1 can exert an antioxidant effect and protect vascular endothelial cells, and can provide a candidate drug for the prevention and treatment of cardiovascular and cerebrovascular diseases such as hypertension, coronary heart disease, cerebral thrombosis, myocardial infarction, atherosclerosis and heart failure.

The present disclosure provides novel small molecule compounds with six-membered aromatic substituents that can serve as inhibitors of lactate dehydrogenase. The present disclosure also provides pharmaceutical compositions, comprising at least one of such novel substituted compounds, and methods of using at least one of such compounds or compositions in treating or preventing diseases associated with lactate dehydrogenase activities, such as primary hyperoxaluria.

To provide a method for preventing deterioration after opening an activity-measuring reagent of lactic acid dehydrogenase, in which accurate measurement result (measured value) not affected by carbon dioxide in the atmosphere even after opening can be obtained, a measured value not deviated from an IFCC SOP method-measuring reagent can be shown, and then, reagent blank does not rise with time.SOLUTION: In an activity-measuring reagent of lactic acid dehydrogenase, 2-amino-2-methyl-1,3-propanediol is used as buffer solution.SELECTED DRAWING: None

The application discloses a clinical biochemical composite quality control product, which comprises detection item raw materials, a matrix liquid and a protective agent; the detection item raw materials are alkaline phosphatase, amylase, sodium glycocholate, cholinesterase, creatinine, leucine aminopeptidase, lactate dehydrogenase, lipase, triglyceride, cholesterol, uric acid, urea, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, glucose, alpha-hydroxybutyric acid dehydrogenase, sodium hydrogen phosphate, magnesium chloride, calcium chloride, ferrous chloride, bilirubin, pancreatic amylase and sodium bicarbonate; the matrix liquid is bovine serum albumin and human serum albumin; and the protective agent is dithiothreitol (DTT), mannitol, trehalose, sodium chloride, a composite enzyme stabilizer AES and sodium azide. The quality control product can realize the detection of 27 clinical biochemical items, and the freeze-drying process is adopted, so that the freeze-dried composite quality control product has low viscosity, is easy to be re-dissolved and mixed, has high stability and has small matrix effect.

The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amound of compound of the formulaand pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.

This invention discloses the application of a flavonoid compound from Citrus aurantium, specifically the application of a flavonoid compound from Citrus aurantium or its physiologically acceptable salt in the preparation of anti-inflammatory and / or therapeutic drugs for diseases related to lactate dehydrogenase release. The flavonoid compound from Citrus aurantium has the structural formula shown in Formula I, wherein R1 is selected from methoxy, hydrogen, ethoxy, or hydroxy; R2 is selected from methoxy, hydrogen, ethoxy, or hydroxy; R3 is selected from methoxy, hydrogen, ethoxy, or hydroxy; R4 is selected from methoxy, hydrogen, ethoxy, or hydroxy; R5 is selected from methoxy, hydrogen, ethoxy, or hydroxy; R6 is selected from methoxy, hydrogen, ethoxy, or hydroxy; and the C2-C3 bond is a double bond or a saturated bond. This invention clarifies that among the flavonoid compounds from Citrus aurantium, isopyroside, apigenin, norihesperidin, hesperidin, and isohesperidin can significantly inhibit LPS-induced LDH release in HL-1 cells and can serve as lead compounds for antiseptic myocardial injury drugs.

The present invention discloses a genetically engineered bacterium producing 1,3-butanediol and its application, belonging to the field of genetic engineering technology. A genetically engineered bacterium producing 1,3-butanediol disclosed in the present invention, with JM109 (DE3) as the starting strain, weakens the citrate synthase gene gltA; knocks out the D-lactate dehydrogenase gene ldhA and the pyruvate dehydrogenase ubiquinone gene poxB; overexpresses the phosphoketolase gene xfp, the phosphotransacetylase gene pta, PhaA, PhaB, Bld*, yqhd, fdh1, nadk, pntA, pntB gene. The genetically engineered bacterium constructed using the present invention produces 1,3-butanediol with high conversion rate, good economy, sustainability and ease of industrial production.

This invention discloses the application of primrosein in the preparation of drugs for the treatment of liver fibrosis. The chemical name of primrosein is 2-methoxy-6-pentyl-1,4-benzoquinone, and its molecular formula is C2. 12 O3H 16 Cellular experiments showed that primrosein reduced the proliferative activity of hepatic stellate cells but did not increase the release of lactate dehydrogenase from hepatic stellate cells, and had no significant inhibitory effect on hepatocyte proliferation. Animal experiments showed that primrosein reduced serum levels of markers in carbon tetrachloride-induced liver fibrosis model mice, decreased collagen fiber content in their liver tissue, and inhibited the expression of hepatic stellate cell activation markers, demonstrating excellent anti-liver fibrosis effects. This indicates that primrosein can be used to prepare effective drugs for the treatment of liver fibrosis.

The present application relates to the technical field of bioengineering, and particularly relates to a recombinant Saccharomyces cerevisiae and a construction method and application thereof, comprising the following steps: step one, using the whole genome of Enterococcus faecalis as a template, a recombinant strain SC1-1 is constructed; step two, using the recombinant strain SC1-1 as a primary strain, L-lactate dehydrogenase CYB2 gene of Saccharomyces cerevisiae is knocked out to obtain a recombinant strain SC2; step three, using the recombinant strain SC2 as a primary strain, branched-chain-2-oxo acid decarboxylase THI3 gene of Saccharomyces cerevisiae is knocked out to obtain a recombinant strain SC3; step four, using the whole genome of Saccharomyces cerevisiae as a template, a recombinant strain SC4 is constructed. The present application innovatively optimizes the source of L-lactate dehydrogenase L-LDH, knocks out L-lactate dehydrogenase CYB2 and branched-chain-2-oxo acid decarboxylase THI3, overexpresses pyruvate kinase CDC19 and H(+)-ATPase PMA2, and makes the L-lactic acid production of Saccharomyces cerevisiae increase to 33.45 g / L.

The invention discloses an application of praquinmod in preparation of drugs for sensitizing esophageal cancer radiotherapy, relates to the technical field of medicines, and innovatively applies praquinmod in the treatment field of X-ray tumor radiotherapy. Experimental data show that on the esophageal cancer cell and organoid level, through Passimod pretreatment, tumor cell proliferation can be significantly inhibited after radiation, tumor cell activity can be reduced, lactic dehydrogenase (LDH) release in tumor cells can be promoted, the tumor cell apoptosis rate can be increased, the proliferation speed of organoid is slowed down, and the size and shape of organoid are further damaged; meanwhile, through the pretreatment of the parinumod, the influence on normal esophageal cells after radiation is completely opposite. The invention shows that the parinumod has obvious sensitization effect and anti-side-effect potential in the esophageal cancer radiotherapy, and proves that the parinumod has potential application value and development prospect in the esophageal cancer radiotherapy aspect.

The application discloses an in-vitro RNA interference method for a Taenia solium lactate dehydrogenase gene, related reagents, a preparation method and uses. The reagent for reducing expression of the Taenia solium lactate dehydrogenase gene can specifically interfere with an EmLDH-B gene, and provides a new idea for in-depth research on a Taenia solium infection mechanism and development of a potential treatment target.

The present application relates to the use of glial fibrillary acidic protein and lactate dehydrogenase A subtype in the preparation of a kit for diagnosing craniocerebral trauma, and provides the use of glial fibrillary acidic protein and lactate dehydrogenase A subtype as a combined indicator in the preparation of a diagnostic kit for diagnosing craniocerebral trauma. The present application also provides the use of reagents for detecting glial fibrillary acidic protein and lactate dehydrogenase A subtype in the preparation of a diagnostic kit for diagnosing craniocerebral trauma. The present application also provides the use of anti-glial fibrillary acidic protein monoclonal antibody and anti-lactate dehydrogenase A subtype monoclonal antibody in the preparation of an immunochromatographic diagnostic kit for diagnosing craniocerebral trauma. The present application simultaneously detects two biomarkers, GFAP and LDHA, in peripheral blood samples, thereby rapidly determining whether craniocerebral injury has occurred, and classifying the severity based on the detection results, to provide a rapid, objective and portable detection means for clinical emergency, pre-hospital emergency and hierarchical management.

According to a sepsis mouse model, it is found that phytolaccin can reduce the liver necrosis area and the inflammatory focus caused by sepsis by reducing the content of alanine aminotransferase, glutamic oxalacetic transaminase, serum creatinine and lactic dehydrogenase, so that the application of phytolaccin to preparation of the medicine for treating sepsis is achieved, and the application of phytolaccin to preparation of the medicine for treating sepsis is achieved. The lung inflammation, alveolar wall thickening and inflammatory cell infiltration are improved, so that the organ injury caused by sepsis is relieved. Meanwhile, the phytolaccin can also regulate the polarization state of macrophages to a balanced state in an inflammatory storm state, so that the release of proinflammatory factors is inhibited, and the effect of preventing and treating sepsis is achieved.

The present invention discloses an application of inhibitors of glycolytic pathway in preparing drugs for preventing and treating porcine reproductive and respiratory syndrome virus (PRRSV) infection. The present invention found that the inhibitors of glycolytic pathway can be used to prevent and treat PRRSV infection, especially, oral administration of the lactate dehydrogenase inhibitor, sodium oxamate or Galloflavin, can significantly inhibit PRRSV replication in pigs, and the present invention found a new use of the inhibitors of glycolytic pathway, especially the lactate dehydrogenase inhibitor (sodium oxamate or Galloflavin), as a PRRSV antagonist for the first time. The sodium oxamate and Galloflavin have clear anti-PRRSV medicinal ingredients, are quality controllable, safe and non-toxic, and have a good application prospect in prevention and treatment of PRRSV.

This invention discloses albumin nanoparticles co-loaded with flavin and lactate oxidase, their preparation method, and applications. Using human serum albumin as a carrier, flavin and lactate oxidase are simultaneously encapsulated at a mass ratio of 10:1, with a particle size of 150-180 nm and a polydispersity index of less than 0.2. This invention exerts its anti-hepatocellular carcinoma effect through mechanisms such as reducing lactate levels in the tumor microenvironment, inducing an increase in reactive oxygen species, inhibiting cGAS protein lactation modification, and activating the cGAS-STING signaling pathway. The nanoparticles exhibit high encapsulation efficiency and good stability. The flavin loaded on these nanoparticles can significantly reduce the reduction of pyruvate to lactate by inhibiting lactate dehydrogenase; simultaneously, the lactate oxidase loaded on these nanoparticles catalyzes the dehydrogenation of lactate to pyruvate. In other words, these nanoparticles synergistically regulate lactate metabolism through a two-way regulatory strategy of "reducing source and increasing sink"—"inhibiting lactate production" and "promoting lactate clearance"—significantly enhancing in vitro and in vivo anti-tumor effects, and demonstrating high biosafety.

The present disclosure provides novel small molecule compounds with six-membered aromatic substituents that can serve as inhibitors of lactate dehydrogenase. The present disclosure also provides pharmaceutical compositions, comprising at least one of such novel substituted compounds, and methods of using at least one of such compounds or compositions in treating or preventing diseases associated with lactate dehydrogenase activities, such as autoimmune diseases.